Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.

Lauro A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Amaduzzi A, Cucchetti A, La Barba G, Grazi GL, D'Errico A, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Di Simone M, Faenza S, Pironi L, Pinna AD.

Transplant Proc. 2007 Jun;39(5):1629-31.

PMID:
17580204
2.

Intestinal transplantation before and after the introduction of sirolimus.

Fishbein TM, Florman S, Gondolesi G, Schiano T, LeLeiko N, Tschernia A, Kaufman S.

Transplantation. 2002 May 27;73(10):1538-42.

PMID:
12042637
3.

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.

Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA.

Am J Transplant. 2006 Mar;6(3):514-22.

4.

Results of intestinal and multivisceral transplantation in adult patients: Italian experience.

Lauro A, Dazzi A, Ercolani G, Cescon M, D'Errico A, Di Simone M, Grazi GL, Vivarelli M, Varotti G, De Ruvo N, Masetti M, Cautero N, Di Benedetto F, Siniscalchi A, Begliomini B, Lazzarotto T, Faenza S, Pironi L, Pinna AD.

Transplant Proc. 2006 Jul-Aug;38(6):1696-8.

PMID:
16908252
5.
6.

Evolutionary experience with immunosuppression in pediatric intestinal transplantation.

Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.

J Pediatr Surg. 2005 Jan;40(1):274-9; discussion 279-80.

PMID:
15868597
7.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
8.

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

Vitko S, Wlodarczyk Z, Kyllönen L, Czajkowski Z, Margreiter R, Backman L, Perner F, Rigotti P, Jaques B, Abramowicz D, Kessler M, Sanchez-Plumed J, Rostaing L, Rodger RS, Donati D, Vanrenterghem Y.

Am J Transplant. 2006 Mar;6(3):531-8.

9.

Replacing calcineurin inhibitors with mTOR inhibitors in children.

Sindhi R, Seward J, Mazariegos G, Soltys K, Seward L, Smith A, Kosmach B, Venkataramanan R.

Pediatr Transplant. 2005 Jun;9(3):391-7.

PMID:
15910398
10.

Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.

MacDonald AS.

Transplant Proc. 2003 May;35(3 Suppl):201S-208S. Review.

PMID:
12742497
11.

Liver transplantation using sirolimus and minimal corticosteroids (3-day taper).

Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I.

Liver Transpl. 2001 Apr;7(4):343-51.

12.

Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.

Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J.

Transplantation. 2008 May 15;85(9):1290-3. doi: 10.1097/TP.0b013e31816dd450.

PMID:
18475186
13.

A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.

Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS, Ramicone E, Fong TL.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):513-20.

14.

Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients.

Lo A, Egidi MF, Gaber LW, Gaber AO.

Transplant Proc. 2003 May;35(3 Suppl):105S-108S.

PMID:
12742477
15.

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group.

Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.

PMID:
19005398
16.

Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation.

Boillot O, Baulieux J, Wolf P, Messner M, Cherqui D, Gugenheim J, Pageaux G, Belghiti J, Calmus Y, Le Treut Y, Neau-Cransac M, Samuel D.

Clin Transplant. 2001 Jun;15(3):159-66.

PMID:
11389705
17.

Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.

Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ.

Hepatobiliary Pancreat Dis Int. 2007 Aug;6(4):376-8.

18.
19.
20.

Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.

Gillard P, Ling Z, Mathieu C, Crenier L, Lannoo M, Maes B, Roep B, Gorus F, Pipeleers D, Keymeulen B.

Transplantation. 2008 Jan 27;85(2):256-63. doi: 10.1097/TP.0b013e31815e8926.

PMID:
18212631

Supplemental Content

Support Center